Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026

Larimar Therapeutics, Inc.

Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.
FDA discussions initiated for using tissue frataxin as surrogate endpoint for accelerated approval; BLA submission targeted for 2H 2025.
Open-label extension (OLE) study of 25 mg daily nomlabofusp dosed first patient in March 2024; interim data expected Q4 2024.
Raised $161.6M net proceeds from public offering in Feb 2024; cash position $86.8M at Dec 31, 2023 before offering.
Q4 2023 net loss $13.0M ($0.30/share) vs $9.4M ($0.21/share) in Q4 2022; R&D expenses $10.6M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported the fourth quarter of 2023 and for the year ended December 31, 2023 results: net income $13.0 million, EPS $0.30 per share.

Period: the fourth quarter of 2023 and for the year ended December 31, 2023
Net income: $13.0 million
EPS: $0.30 per share
Result: reported results

Exact text from the filing

The Company reported a net loss for the fourth quarter of 2023 of $13.0 million, or $0.30 per share, compared to a net loss of $9.4 million, or $0.21 per share, for the fourth quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-031467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.